首页 > 市场调查报告书 > 製药

再生医学细胞疗法

亚太地区T 细胞治疗市场预测至2030 年- 区域分析- 按模式（研究和商业化）、治疗类型[CAR T 细胞疗法和基于T 细胞受体(TCR) 的] 和适应症（血液恶性肿瘤和实体瘤）

市场调查报告书

商品编码

1452623

亚太地区T 细胞治疗市场预测至2030 年- 区域分析- 按模式（研究和商业化）、治疗类型[CAR T 细胞疗法和基于T 细胞受体(TCR) 的] 和适应症（血液恶性肿瘤和实体瘤）

Asia Pacific T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

出版日期: 2024年01月15日 | 出版商:

The Insight Partners | 英文 76 Pages | 订单完成后即时交付

价格

简介目录图表

2022年亚太地区T细胞治疗市场估值为2.5199亿美元，预计2030年将达8.8272亿美元；预计2022年至2030年CAGR为17.0%。

T 细胞治疗核准数量的增加推动了亚太地区 T 细胞治疗市场的发展

标靶治疗、更快、更有效的恢復以及减少副作用都是 T 细胞疗法的优点。在全球范围内，由于获得了各种批准，细胞疗法被广泛采用。例如，2023年：杨森的CAR-T细胞疗法CARVYKTI（Ciltacabtagene Autoleucel）已被澳洲治疗产品管理局批准作为多发性骨髓瘤患者的四线治疗。

2023年：中国国家药品监督管理局核准信达生物及IASO生物技术公司（IASO Bio）的Fucaso（equecabtagene autoleucel）用于治疗成人復发或难治性多发性骨髓瘤（RRMM）患者。 2023年6月，该机构批准了该疗法的新药申请（NDA）。

2023年：第一个人源化CD19靶向嵌合抗原受体T细胞（CAR-T细胞）治疗产品NexCAR19（Actalycabtagene autoleucel）已获得中央药品标准控制组织（CDSO）批准用于治疗復发/难治性癌症印度的 B 细胞淋巴瘤和白血病。免疫过继性细胞疗法在印度理工学院孟买分校孵化。

2023年：復星凯特生物科技研发的自体CAR T细胞疗法益凯达（axicabtagene ciloleucel）获得中国国家药品监督管理局（NMPA）批准用于大B细胞淋巴瘤患者的二线治疗。

2020 年：日本厚生劳动省 (MHLW) 向神户生物医学研究与创新基金会 (“FBRI”) 授予行销许可证，为日本患者生产和分销 Kymriah (tisagenlecleucel)。诺华公司今天宣布了这项消息。凭藉这项许可，FBRI 现在成为亚洲唯一授权的 CAR-T 细胞疗法商业生产工厂。

因此，越来越多的 T 细胞疗法获批正在推动市场成长。

亚太地区T细胞治疗市场概况

亚太地区 T 细胞治疗市场分为中国、日本、印度、韩国、澳洲和亚太其他地区。由于 CAR T 细胞疗法可有效治疗癌症，从而推动该地区的市场成长，预计亚太地区市场将显着成长。该地区正在进行许多 CAR T 细胞疗法的临床试验，这为亚太地区提供了新的机会。中国是全球开展CAR T细胞临床试验最多的国家，医院进行的临床试验也最多。中国正在形成 CAR-T 产业链，包括正在进行和预期的监管改革，以有利于获得此类新疗法。中国于2021 年9 月批准了JW Therapeutics 的首个CAR T 细胞疗法relmacabtagene autoleucel，用于治疗经过两种或多种全身治疗后的复发或难治性大B 细胞淋巴瘤(r/r LBCL) 成人患者。

亚太地区 T 细胞治疗市场收入及 2030 年预测（百万美元）

亚太地区T细胞治疗市场区隔

亚太地区 T 细胞治疗市场分为模式、治疗类型、适应症和国家。

根据模式，亚太 T 细胞治疗市场分为研究和商业化。 2022年，商业化细分市场将占据更大的市场份额。

根据治疗类型，亚太地区T细胞治疗市场分为CAR T细胞疗法和T细胞受体（TCR）疗法。 2022年，CAR T细胞疗法领域将占据更大的市场份额。

根据适应症，亚太地区 T 细胞治疗市场分为血液恶性肿瘤和实体肿瘤。 2022 年，血液恶性肿瘤细分市场占据最大市场。

依国家/地区划分，亚太地区 T 细胞治疗市场分为中国、日本、澳洲、韩国和亚太地区其他地区。 2022年，中国在亚太T细胞治疗市场占据主导地位。

百时美施贵宝公司、吉利德科学公司、信达生物製品公司、杨森全球服务有限责任公司、JW（开曼）治疗有限公司、传奇生物科技公司和诺华公司是亚太地区T 细胞治疗市场上的一些领先公司。

Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of t cell therapy. Globally, cell therapies are widely adopted owing to the availability of various approvals. For instance, in 2023: Janssen's CAR-T cell therapy CARVYKTI (Ciltacabtagene Autoleucel) has been approved as a fourth-line treatment for multiple myeloma patients by the Therapeutic Goods Administration, Australia.

In 2023: The Chinese National Medical Products Administration has approved the use of Fucaso (equecabtagene autoleucel) by Innovent Biologics and IASO Biotechnology (IASO Bio) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). In June 2023, the agency approved the therapy's new drug application (NDA).

In 2023: The first humanized CD19-targeted Chimeric Antigen Receptor T cell (CAR-T cell) therapy product, NexCAR19 (Actalycabtagene autoleucel), has been approved by the Central Drugs Standard Control Organization (CDSO) for use in cases of relapsed/refractory B-cell lymphomas and leukemia in India. Immuno Adoptive Cell Therapy is incubated at IIT Bombay.

In 2023: Yikaida (axicabtagene ciloleucel), an autologous CAR T-cell therapy developed by Fosun Kite Biotechnology, was granted approval by China's National Medical Products Administration (NMPA) for use as a second-line treatment for patients with large B-cell lymphoma.

In 2020: The Ministry of Health, Labor and Welfare (MHLW) of Japan has granted the Foundation for Biomedical Research and Innovation at Kobe ("FBRI") a marketing license to produce and distribute Kymriah (tisagenlecleucel) for patients in Japan. Novartis made this announcement today. With this clearance, FBRI is now the only authorized commercial manufacturing facility in Asia for CAR-T cell therapy.

Thus, the increasing number of approvals for T-cell therapy is fueling the market growth.

Asia Pacific T Cell Therapy Market Overview

The Asia Pacific T-cell therapy market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market in Asia Pacific is expected to witness significant growth as CAR T-cell therapy is efficient in treating cancer, elevating the market growth in the region. Many clinical trials for CAR T-cell therapy are ongoing in the region, offering new opportunities in APAC. China is the largest country in the world for CAR T-cell clinical trials, which hospitals conduct. The CAR-T industry chain is being formed in China, including ongoing and expected regulatory reforms to benefit access to such novel therapies. China approved its first CAR T-cell therapy, relmacabtagene autoleucel of JW Therapeutics, in September 2021 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy.

Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

Asia Pacific T Cell Therapy Market Segmentation

The Asia Pacific T cell therapy market is segmented into modality , therapy type, indication, and country.

Based on modality, the Asia Pacific T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the Asia Pacific T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the Asia Pacific T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the Asia Pacific T cell therapy market is segmented into China, Japan, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific T cell therapy market in 2022.

Bristol-Myers Squibb Co, Gilead Sciences Inc, Innovent Biologics Inc, Janssen Global Services LLC, JW (Cayman) Therapeutics Co Ltd, Legend Biotech Corp, and Novartis AG are some of the leading companies operating in the Asia Pacific T cell therapy market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Asia Pacific T Cell Therapy Market, by Country (US$ Million)

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific T Cell Therapy Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Growing Burden of Cancer Worldwide
- 4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
- 4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
- 4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
- 4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:

5. T Cell Therapy Market - Asia Pacific Market Analysis

5.1 Asia Pacific T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030

6. Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality.

6.1 Overview
6.2 Asia Pacific T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
- 6.3.1 Overview
- 6.3.2 Research: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
- 6.4.1 Overview
- 6.4.2 Commercialized: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type

7.1 Overview
7.2 Asia Pacific T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
- 7.3.1 Overview
- 7.3.2 CAR T-cell Therapy: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
- 7.4.1 Overview
- 7.4.2 T-cell Receptor (TCR)-based: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication.

8.1 Overview
8.2 Asia Pacific T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
- 8.3.1 Overview
- 8.3.2 Hematologic Malignancies: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
- 8.3.3 Asia Pacific T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
- 8.4.1 Overview
- 8.4.2 Solid Tumor: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific T Cell Therapy Market - Country Analysis

9.1 Overview

10. T Cell Therapy Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Legend Biotech Corp
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Janssen Global Services LLC
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Gilead Sciences Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Bristol-Myers Squibb Co
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Novartis AG
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 JW (Cayman) Therapeutics Co Ltd
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Innovent Biologics Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. Asia Pacific T Cell Therapy Market Segmentation
Table 2. Asia Pacific T Cell Therapy Market, by Hematological Malignancies - Revenue and Forecast to 2030 (US$ Million)
Table 3. FDA-Approved Autologous CAR T-Cell Therapies Registered in Asia Pacific
Table 4. China: Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 5. China: Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 6. China: Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 7. China: Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 8. Japan: Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 9. Japan: Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 10. Japan: Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 11. Japan: Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 12. Australia: Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 13. Australia: Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 14. Australia: Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 15. Australia: Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 16. South Korea: Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 17. South Korea: Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 18. South Korea: Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 19. South Korea: Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 20. Rest of Asia Pacific: Asia Pacific T Cell Therapy Market, by Modality - Revenue and Forecast to 2030 (US$ Million)
Table 21. Rest of Asia Pacific: Asia Pacific T Cell Therapy Market, by Therapy Type - Revenue and Forecast to 2030 (US$ Million)
Table 22. Rest of Asia Pacific: Asia Pacific T Cell Therapy Market, by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Asia Pacific: Asia Pacific T Cell Therapy Market, For Hematologic Malignancies by Indication - Revenue and Forecast to 2030 (US$ Million)
Table 24. Recent Organic Growth Strategies in Asia Pacific T Cell Therapy Market
Table 25. Recent Inorganic Growth Strategies in the Asia Pacific T Cell Therapy Market
Table 26. Glossary of Terms, Asia Pacific T Cell Therapy Market

List Of Figures

Figure 1. Asia Pacific T Cell Therapy Market Segmentation, By Country
Figure 2. Asia Pacific T Cell Therapy Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific T Cell Therapy Market Revenue (US$ Mn), 2022 - 2030
Figure 5. Asia Pacific T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
Figure 6. Research: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Commercialized: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Asia Pacific T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
Figure 9. CAR T-cell Therapy: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. T-cell Receptor (TCR)-based: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Asia Pacific T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 12. Hematologic Malignancies: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Solid Tumor: Asia Pacific T Cell Therapy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Asia Pacific T Cell Therapy Market, by Key Country - Revenue, 2022 (US$ Million)
Figure 15. Asia Pacific T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 16. China: Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. Japan: Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 18. Australia: Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. South Korea: Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. Rest of Asia Pacific: Asia Pacific T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Growth Strategies in T Cell Therapy Market